采用多克隆抗体Ｎ２１对２１７例乳腺良、恶性肿瘤作了癌基因ｃ－ｅｒｂＢ－２表达产物的免疫组化研究。结果发现：１６７例乳腺癌中６６例（３９．５２％）ｃ－ｅｒｂＢ－２有过度表达，全部为浸润性导管癌。５０例乳腺良性病变ｃ－ｅｒｂＢ－２全部为阴性。ｃ－ｅｒｂＢ－２过度表达与组织学细胞分级、淋巴结转移度、死亡率、复发率呈正相关，统计学检验差异有高度显著性。且用ｃ－ｅｒｂＢ－２表达情况优于用淋巴结转移来观测乳腺癌预后，但两者联合应用则更为全面有效 The polyclonal antibody N21 was used to investigate the expression of c-erbB-2 in 217 breast benign and malignant tumors. The results showed that 66 cases (39.52%) of c-erbB-2 were overexpressed in 167 cases of breast cancer, all of which were infiltrating ductal carcinoma. All 50 cases of benign breast lesions were negative for c-erbB-2. The overexpression of c-erbB-2 was positively correlated with the histological grade, lymph node metastasis, mortality, and recurrence rate, and the statistically significant differences were statistically significant. And the expression of c-erbB-2 is better than the use of lymph node metastasis to observe the prognosis of breast cancer, but the combination of the two is more comprehensive and effective.